Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition

Targeting the human epidermal growth factor receptor 2 (HER2) became a landmark in the treatment of HER2-driven breast cancer. Nonetheless, the clinical efficacy of anti-HER2 therapies can be short-lived and a significant proportion of patients ultimately develop metastatic disease and die. One stri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research communications 2022-03, Vol.2 (3), p.131-145
Hauptverfasser:	Zhang, Jingwei, Pearson, Adam J, Sabherwal, Nitin, Telfer, Brian A, Ali, Nisha, Kan, Karmern, Xu, Qiuping, Zhang, Wei, Chen, Fuhui, Li, Shiyang, Wang, Jinhua, Gray, Nathanael S, Risa-Ebrí, Blanca, Finegan, Katherine G, Cross, Michael J, Giurisato, Emanuele, Whitmarsh, Alan J, Tournier, Cathy
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!